# Crinetics Pharmaceuticals Type: Company (CRNX) Source: GetYourBrief — https://getyourbrief.com/entity/crinetics-pharmaceuticals Canonical HTML page: https://getyourbrief.com/entity/crinetics-pharmaceuticals ## Timeline - **2026-07**: Vertex announces $10 billion acquisition of Crinetics — Vertex Pharmaceuticals agrees to buy Crinetics Pharmaceuticals for $10 billion in cash, gaining a pipeline of endocrine therapies; the deal has not yet closed. - **2026-02-26**: EU Expansion — Positive CHMP opinion received, enabling commercialization in the European Union. - **2026-01-15**: Public Offering — Crinetics raises capital, bringing total cash position to $1.4 billion. - **2026**: NDA Submission — Planned submission of paltusotine New Drug Application to the FDA. - **2026**: Phase 3 Initiation — Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease. - **2025-12-31**: Q4 Milestone — Over 200 enrollment forms and 125 unique prescribers recorded for Palsonify. - **2025-Q4**: Earnings Call — Management confirms commercial readiness and pipeline acceleration. - **2025-10-01**: Palsonify Launch — Crinetics initiates U.S. commercial launch of Palsonify for acromegaly. - **2025-Q3**: PATHFNDR-2 Success — Completion of Phase 3 trial for paltusotine in acromegaly with positive results. ## Recent coverage (9 stories, network-wide) ### VKTX Stock: The $10B Vertex-Crinetics Deal Warms Up a $20B Viking Takeover 2026-07-31 06:15:41 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2 Vertex's $10B cash acquisition of Crinetics sets a powerful precedent, suggesting Viking Therapeutics could command a $15–20B price tag in a consolidating obesity market. For investors, VKTX's late-stage pipeline and the appetite of cash-rich pharma giants offer a high-risk, high-reward M&A setup. Full story: https://getfinancebrief.com/story/viking-therapeutics-stock-vertex-crinetics-acquisition-finance ### Viking's $190B Obesity Pipeline Beckons: Could It Be the Next $10B Biotech Buyout? 2026-07-31 06:14:04 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 Vertex's $10B buyout of Crinetics highlights the frenzied demand for metabolic pipelines. Viking Therapeutics, with a Phase 3 obesity asset and an oral candidate nearing late-stage trials, now looks like the most logical next takeover target in the rapidly expanding $190B weight-loss market. Full story: https://getbiobrief.com/story/viking-therapeutics-vertex-crinetics-obesity-acquisition-bio ### Nasdaq Falls 1.2% as AI Chip Carnage Fuels Cloud Spending ROI Doubts 2026-07-11 23:43:27 · Sector: saas · Sentiment: Negative · Impact: 7/10 · Sources: 8 The 1.2% Nasdaq drop, driven by 6-10% plunges in AMD, Intel, and Micron, reflects growing fears that massive AI infrastructure investments may not yield proportionate returns. For SaaS and cloud providers that have hitched growth narratives to AI-driven demand, the sell-off raises urgent questions about the sustainability of enterprise software spending. Full story: https://getsaasbrief.com/story/nasdaq-1-2-pct-saas-cloud-capex ### Samsung’s 1,800% Profit Jump Can’t Halt AI Stock Rout as Nasdaq Sinks 1.2% 2026-07-11 23:43:13 · Sector: ai · Sentiment: Negative · Impact: 7/10 · Sources: 8 Even a jaw-dropping 1,800% YoY operating profit forecast from Samsung couldn’t prop up AI stocks on July 7, as the sector’s inflated valuations met a harsh reality check. The 6.9% drop in Seoul and subsequent 6-10% declines in U.S. chipmakers signal that the AI industry must now prove its ROI potential to justify its sky-high market caps. Full story: https://getaibrief.com/story/samsung-1800-profit-ai-selloff ### AI Infrastructure and Specialized Hardware Drive Q4 2025 Earnings Growth 2026-02-27 02:16:23 · Sector: ai · Sentiment: Positive · Impact: 7/10 · Sources: 11 Q4 2025 earnings reports highlight a strategic shift toward AI-integrated hardware and high-margin services, with Aeva securing a pivotal NVIDIA partnership and Arlo achieving record SaaS metrics. Meanwhile, Crinetics successfully launched Palsonify, backed by a massive $1.4 billion cash reserve to fuel global expansion. Full story: https://getaibrief.com/story/ai-infrastructure-hardware-q4-2025-earnings ### Hardware-to-SaaS Pivot Drives Q4 Growth for Arlo and AI Infrastructure Firms 2026-02-27 02:10:26 · Sector: saas · Sentiment: Positive · Impact: 7/10 · Sources: 11 The Q4 2025 earnings cycle highlights a significant shift toward recurring revenue and high-performance computing (HPC) across the hardware and biotech sectors. Arlo Technologies achieved a landmark Rule of 40 score, while TeraWulf and Aeva Technologies signaled deeper integrations into the AI infrastructure ecosystem. Full story: https://getsaasbrief.com/story/saas-cloud-earnings-q4-2025-arlo-terawulf-crinetics ### Q4 Retail & Tech Earnings: DTC Strength and Industrial Scaling Drive Growth 2026-02-27 02:07:35 · Sector: retail · Sentiment: Positive · Impact: 7/10 · Sources: 11 The Q4 2025 earnings season highlights a divergence between high-growth DTC brands like FIGS and Arlo, which are successfully leveraging recurring services, and industrial tech firms like PureCycle and Aeva transitioning into full-scale production. While margin pressures from tariffs persist, robust cash positions and strategic partnerships with giants like NVIDIA are fortifying market leaders. Full story: https://getretailbrief.com/story/q4-2025-retail-tech-earnings-analysis ### Crinetics (CRNX) Advances Toward Commercialization Amid Q4 2025 Earnings Wave 2026-02-27 01:35:34 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3 Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape. Full story: https://getfinancebrief.com/story/crinetics-crnx-q4-2025-earnings-analysis ### Crinetics Signals Commercial Readiness as Lead Candidates Near FDA Submission 2026-02-27 01:34:00 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3 Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant. Full story: https://getbiobrief.com/story/crinetics-crnx-q4-2025-earnings-pipeline-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.